Visualize your facility’s constraints, accommodate variability, maximize production, and understand the implications of any change in the manufacturing process.
As cell and gene therapy product pipelines grow, available CMO capacity can be severely constrained, especially for smaller companies. As a result, many sponsors are being forced to bring manufacturing in-house—or reluctantly accept a long and costly delay to their trials. Furthermore, these new products require significantly more complex manufacturing processes than traditional small or large molecule products.
Realize These Benefits:
